ImmunoPrecise Antibodies Ltd.
- Biotech or pharma, therapeutic R&D
- IT, information
- CMO, CRO
- Diagnostics
- Other R&D services
IPA is an AI drug discovery company combining advanced wet-lab capabilities with its proprietary AI platform, LENSai™, to streamline therapeutic antibody development. We offer AI-powered de novo antibody discovery, enabling the design of novel therapeutics tailored to your targets.
LENSai™ also delivers rapid and accurate in silico epitope mapping, reliable immunogenicity prediction, developability profiling, and customized engineering, reducing timelines from weeks to hours (see attached slide deck for details).
IPA is actively seeking strategic partnerships on AI drug discovery, and offers a portfolio of antibody assets for out-licensing.
Let’s connect to explore how we can support your pipeline.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}